Meritain Eldorado policies

Search Meritain Eldorado's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

106 policies name 96365, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Eldorado policies
PolicyDetailsCodesSource
0964-Crizanlizumab-tmca (Adakveo)0964 · Commercial2Original policy ↗
0988-Trilaciclib (Cosela)0988 · Commercial2Original policy ↗
Histamine Desensitization Therapy for Intractable Headaches0647 · Commercial2Original policy ↗
0914-Bezlotoxumab (Zinplava)0914 · Commercial3Original policy ↗
0918-Edaravone Injection0918 · Commercial3Original policy ↗
0938-Ketamine for the Treatment of Depression and Other Selected Indications0938 · Commercial3Original policy ↗
0951-Brexanolone (Zulresso)0951 · Commercial3Original policy ↗
0976-Plasminogen, Human-tvmh (Ryplazim)0976 · Commercial3Original policy ↗
1020-Sodium Thiosulfate (Pedmark)1020 · Commercial3Original policy ↗
1043-Pozelimab-bbfg (Veopoz)1043 · Commercial3Original policy ↗
0970-Eptinezumab-jjmr (Vyepti)0970 · Commercial4Original policy ↗
1005-Tebentafusp-tebn (Kimmtrak)1005 · Commercial5Original policy ↗
Denileukin Diftitox-cxdl (Lymphir)1070 · Commercial5Original policy ↗
0794-Ofatumumab (Arzerra)0794 · Commercial6Original policy ↗
0709-Nesiritide (Natrecor)0709 · Commercial7Original policy ↗
0895-Dinutuximab (Unituxin)0895 · Commercial7Original policy ↗
0982-Remdesivir (Veklury)0982 · Commercial7Original policy ↗
1001-Sirolimus Protein-Bound Particles for Injectable Suspension Albumin-Bound (Fyarro)1001 · Commercial7Original policy ↗
1052-Exagamglogene Autotemcel (Casgevy)1052 · Commercial8Original policy ↗
1053-Lovotibeglogene Autotemcel (Lyfgenia)1053 · Commercial8Original policy ↗
0920-Tisagenlecleucel (Kymriah)0920 · Commercial9Original policy ↗
0974-Ado-trastuzumab emtansine (Kadcyla)0974 · Commercial9Original policy ↗
1032-Omidubicel-onlv (Omisirge)1032 · Commercial9Original policy ↗
0949-Caplacizumab-yhdp (Cablivi)0949 · Commercial10Original policy ↗
0989-Evinacumab-dgnb (Evkeeza)0989 · Commercial10Original policy ↗
1019-Tremelimumab-actl (Imjudo)1019 · Commercial10Original policy ↗
1021-Mirvetuximab Soravtansine-gynx (Elahere)1021 · Commercial10Original policy ↗
0889-Levoleucovorin (Khapzory)0889 · Commercial12Original policy ↗
0936-Ibalizumab-uiyk (Trogarzo)0936 · Commercial12Original policy ↗
0524-Zoledronic Acid0524 · Commercial13Original policy ↗
Coronary Artery Brachytherapy and Other Adjuncts to Coronary Interventions0491 · Commercial13Original policy ↗
Hereditary Angioedema0782 · Commercial14Original policy ↗
0234-Chelation Therapy0234 · Commercial15Original policy ↗
1048-Mirikizumab-mrkz (Omvoh)1048 · Commercial15Original policy ↗
Pulmonary Hypertension Treatments and Selected Indications of Prostanoids0184 · Commercial15Original policy ↗
0834-Paclitaxel, Albumin-Bound0834 · Commercial16Original policy ↗
1022-Teplizumab-mzwv (Tzield)1022 · Commercial16Original policy ↗
1006-Sutimlimab-jome (Enjaymo)1006 · Commercial17Original policy ↗
1018-Teclistamab-cqyv (Tecvayli)1018 · Commercial17Original policy ↗
Gene-Based Therapy for Duchenne Muscular Dystrophy (DMD)0911 · Commercial17Original policy ↗
Neonatal Hyperbilirubinemia0332 · Commercial17Original policy ↗
0748-Panitumumab (Vectibix)0748 · Commercial18Original policy ↗
0948-Emapalumab-lzsg (Gamifant)0948 · Commercial18Original policy ↗
Betibeglogene Autotemcel (Zynteglo)1016 · Commercial18Original policy ↗
1077-Remestemcel-L-rknd (Ryoncil)1077 · Commercial19Original policy ↗
0996-Aducanumab-avwa (Aduhelm)0996 · Commercial20Original policy ↗
1026-Lecanemab-irmb (Leqembi)1026 · Commercial21Original policy ↗
Donanemab-azbt (Kisunla)1066 · Commercial21Original policy ↗
0919-Inotuzumab Ozogamicin (Besponsa)0919 · Commercial22Original policy ↗
1097-Etuvetidigene Autotemcel (Waskyra)1097 · Commercial22Original policy ↗

Back to Meritain Eldorado

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.